Teladoc executive sells $22,500 in company stock

Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock in an open-market transaction at $9.00 per share, totaling $22,500.

Rhea-AI Filing Summary

Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, sold 2,500 shares of common stock in an open-market transaction at $9.00 per share, totaling $22,500. After the sale, she directly holds 87,378 shares. The transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025.

Insights

Equity analyst

Routine 10b5-1 sale of a small portion of Teladoc shares.

Teladoc executive Kelly Bliss conducted an open-market sale of 2,500 common shares at $9.00 per share, for proceeds of about $22,500. Following this transaction, she directly holds 87,378 shares, so the sale covers only a fraction of her position.

The footnote states this trade was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025. Such plans schedule trades in advance, which generally makes the timing less informative about management’s current view of the stock. Overall, this filing reflects a routine, planned disposition rather than a major change in insider ownership.

Insider Trade Summary 10b5-1

Net Seller: 2,500 shares

Net Sell 1 txn

Insider Bliss Kelly

Role President, U.S. Group Health

Sold 2,500 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,500	$9.00	$23K

Holdings After Transaction: Common Stock — 87,378 shares (Direct)

Footnotes (1)

1. F1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on August 14, 2025.

Key Figures

Shares sold: 2,500 shares Sale price: $9.00 per share Sale proceeds: $22,500 +1 more

4 metrics

Shares sold 2,500 shares Open-market sale on 2026-07-01

Sale price $9.00 per share Open-market sale

Sale proceeds $22,500 2,500 shares at $9.00

Shares held after transaction 87,378 shares Direct ownership following sale

Key Terms

Rule 10b5-1 trading plan, open-market sale, Form 4

3 terms

Rule 10b5-1 trading plan financial

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan..."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Teladoc Health (TDOC) report for Kelly Bliss?

Teladoc reported that executive Kelly Bliss sold 2,500 shares of common stock at $9.00 per share. The open-market sale totaled $22,500 and left her with 87,378 directly held shares following the transaction, according to the Form 4 filing.

Was Kelly Bliss’s Teladoc (TDOC) stock sale part of a 10b5-1 trading plan?

Yes. The Form 4 footnote states the transaction was effected under a Rule 10b5-1 trading plan adopted on August 14, 2025. These pre-arranged plans automate trades, which generally reduces the significance of trade timing for interpreting insider sentiment.

How many Teladoc (TDOC) shares does Kelly Bliss hold after the reported sale?

After selling 2,500 Teladoc shares, Kelly Bliss directly holds 87,378 shares. This post-transaction balance, disclosed in the Form 4, shows that the sale represents only a portion of her overall direct equity position in the company.

What price did Kelly Bliss receive per Teladoc (TDOC) share in the Form 4 transaction?

The Form 4 shows that Kelly Bliss’s open-market sale was executed at $9.00 per share. With 2,500 shares sold at this price, the transaction generated $22,500 in gross proceeds before any taxes or commissions that may apply.

What is Kelly Bliss’s role at Teladoc Health (TDOC) related to this Form 4 filing?

Kelly Bliss is listed as an officer of Teladoc Health, serving as President, U.S. Group Health. Her position makes her a reporting person under SEC rules, requiring Form 4 filings to disclose timely changes in her beneficial ownership of Teladoc common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 05:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bliss Kelly

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Group Health

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		2,500	D	$9	87,378	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on August 14, 2025.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)